Koninklijke Philips (NYSE:PHG – Get Free Report) has earned an average rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company.
Several research firms recently issued reports on PHG. StockNews.com lowered Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Jefferies Financial Group raised shares of Koninklijke Philips from an “underperform” rating to a “hold” rating in a research note on Tuesday, October 29th.
Get Our Latest Report on Koninklijke Philips
Institutional Investors Weigh In On Koninklijke Philips
Koninklijke Philips Stock Down 2.6 %
NYSE:PHG opened at $24.92 on Friday. Koninklijke Philips has a 52 week low of $19.55 and a 52 week high of $32.91. The stock’s fifty day moving average is $25.93 and its two-hundred day moving average is $28.08. The stock has a market capitalization of $23.42 billion, a price-to-earnings ratio of -59.33, a price-to-earnings-growth ratio of 0.92 and a beta of 0.77. The company has a quick ratio of 0.74, a current ratio of 1.16 and a debt-to-equity ratio of 0.60.
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Recommended Stories
- Five stocks we like better than Koninklijke Philips
- How to Buy Cheap Stocks Step by Step
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- The Most Important Warren Buffett Stock for Investors: His Own
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.